Resultados de la búsqueda 281-290 of 15526 for LL-37

  1. Hematología - Ensayos clínicos - Mayo Clinic

    Cohort 2 includes (1) muCALR+ primary MF, and (2) muCALR+ secondary MF. ... Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo ...

  2. Ensayos clínicos - Hematología

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  4. Neurología - Ensayos clínicos - Mayo Clinic

    ... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...

  5. Neurología - Ensayos clínicos - Mayo Clinic

    ... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...

  6. Neurología - Ensayos clínicos - Mayo Clinic

    ... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... 2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... 2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a ...

  9. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients will receive VSL#3® 450B sachets probiotics, which will be provided as part of this trial, at least 3 days but preferably 1-2 weeks prior to starting ...